Tergooiziekenhuizen
- Address
- lock Available on a paid plan
Cardiovascular Research
At Tergooiziekenhuizen in Hilversum, a major focus is cardiovascular disease research, including acute myocardial infarction, atherosclerotic cardiovascular disease, peripheral arterial disease, and refractory angina. These studies are mainly designed to test new treatments, reduce heart-related events, and improve long-term outcomes for people at high cardiovascular risk.
- Studies on myocardial infarction and prevention of recurrent heart events
- Research in atherosclerosis, lipoprotein(a), and vascular inflammation
- Trials for coronary artery disease, angina, and peripheral arterial disease
The site also contributes to research on better cardiovascular risk reduction strategies and improved management for patients with complex heart and vessel disease.
Oncology and Hematology
The site has an extensive portfolio in oncology and hematology, with studies in non-small cell lung cancer, breast cancer, prostate cancer, colorectal cancer, renal cell carcinoma, multiple myeloma, and lymphoma. Much of this work is aimed at evaluating new cancer therapies, improving treatment effectiveness, and finding better ways to personalize care.
- Research in lung cancer, including early-stage and advanced disease
- Trials in breast cancer, triple-negative breast cancer, and hormone receptor-positive disease
- Studies in prostate cancer, colorectal cancer, and other advanced solid tumors
- Hematology research in CLL, DLBCL, multiple myeloma, and related blood cancers
Several trials also explore biomarker-guided treatment and more targeted cancer care, reflecting a strong interest in precision oncology at Tergooiziekenhuizen.
Kidney, Metabolic, and Endocrine Disorders
Another important area is kidney disease, type 2 diabetes, obesity, and thyroid disease. These trials are focused on slowing disease progression, improving symptoms, and lowering the risk of serious complications in patients with chronic metabolic and endocrine conditions.
- Studies in chronic kidney disease and kidney-related cardiovascular risk
- Research in type 2 diabetes and associated heart and kidney outcomes
- Trials addressing hypothyroidism and persistent fatigue
- Work on obesity and broader metabolic health
This research aims to improve daily quality of life while also preventing progression to more severe disease.
Women’s Health and Reproductive Medicine
The site also supports studies in women’s health and reproductive medicine, including polycystic ovary syndrome, placenta previa, and preterm birth. These trials are designed to improve pregnancy outcomes, support fertility care, and reduce complications for mothers and babies.
- Research on preventing preterm birth in high-risk pregnancies
- Studies in PCOS and fertility treatment strategies
- Pregnancy-related research involving placenta previa
This area highlights a practical focus on safer, more effective care for women during pregnancy and reproductive treatment.
Infection, Critical Care, and Acute Conditions
Tergooiziekenhuizen is active in studies of sepsis, Staphylococcus aureus bacteremia, and other serious infections, as well as acute neurologic and surgical conditions such as chronic subdural hematoma. The main goal is to improve survival, shorten illness, and refine treatment decisions for hospitalized patients.
- Trials in sepsis and intensive care treatment optimization
- Research on bacteremia and safer antibiotic use
- Studies for chronic subdural hematoma to reduce the need for surgery
These projects reflect a strong interest in better acute-care strategies for patients with complex and potentially life-threatening conditions.
Neurology, Psychiatry, and Patient-Reported Outcomes
The research portfolio also includes mental health and neurologic topics such as depression, treatment response in electroconvulsive therapy, and persistent symptoms that affect everyday functioning. These studies aim to improve treatment tolerability, predict response, and better understand quality of life outcomes.
- Research on depression and severe mood disorders
- Studies seeking to improve outcomes and reduce side effects of ECT
- Work on quality of life and ongoing symptoms after illness
This field combines clinical care with research on how treatments affect patients beyond standard medical outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 24 therapeutic areas and 15 of 157 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 152 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 23 by active trials.
- 1Amsterdam UMC Stichting5active
lock +22 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amsterdam UMC Stichting9trials
lock +13 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Tergooiziekenhuizen
lock Showing 1 of 65 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 157 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 6 | Unknown | 2016-07-25 | 2026-07-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.